В журнале International Journal of Molecular Sciences (IF=5,923) опубликована статья с участием сотрудников Института: А.С. Филимонова (мнс ЛНТПС), д.х.н. О.И. Лузиной (внс ЛФАВ), чл.-корр. РАН, проф. д.х.н. Н.Ф. Салахутдинова (зав.отделом ЛФАВ)
New Hybrid Compounds Combining Fragments of Usnic Acid and Thioether Are Inhibitors of Human Enzymes TDP1, TDP2 and PARP1
Nadezhda S. Dyrkheeva, Aleksandr S. Filimonov, Olga A. Luzina, Kristina A. Orlova,Irina A. Chernyshova,Tatyana E. Kornienko, Anastasia A. Malakhova, Sergey P. Medvedev, Alexandra L. Zakharenko, Ekaterina S. Ilina, Rashid O. Anarbaev, Konstantin N. Naumenko, Kristina V. Klabenkova, Ekaterina A. Burakova, Dmitry A. Stetsenko, Suren M. Zakian,
Nariman F. Salakhutdinov and Olga I. Lavrik
Int. J. Mol. Sci. 2021, 22(21), 11336
Publication Date:October 20, 2021
https://doi.org/10.3390/ijms222111336
(This article belongs to the Special Issue Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach)
Abstract
Tyrosyl-DNA phosphodiesterase 1 (TDP1) catalyzes the cleavage of the phosphodiester bond between the tyrosine residue of topoisomerase 1 (TOP1) and the 3′ phosphate of DNA in the single-strand break generated by TOP1. TDP1 promotes the cleavage of the stable DNA–TOP1 complexes with the TOP1 inhibitor topotecan, which is a clinically used anticancer drug. This article reports the synthesis and study of usnic acid thioether and sulfoxide derivatives that efficiently suppress TDP1 activity, with IC50 values in the 1.4–25.2 μM range. The structure of the heterocyclic substituent introduced into the dibenzofuran core affects the TDP1 inhibitory efficiency of the compounds. A five-membered heterocyclic fragment was shown to be most pharmacophoric among the others. Sulfoxide derivatives were less cytotoxic than their thioester analogs. We observed an uncompetitive type of inhibition for the four most effective inhibitors of TDP1. The anticancer effect of TOP1 inhibitors can be enhanced by the simultaneous inhibition of PARP1, TDP1, and TDP2. Some of the compounds inhibited not only TDP1 but also TDP2 and/or PARP1, but at significantly higher concentration ranges than TDP1. Leader compound 10a showed promising synergy on HeLa cells in conjunction with the TOP1 inhibitor topotecan.
Альметрики:
